MYDECINE
INNOVATIONS GROUP INC.
(the "Company" or
"Mydecine")
TOTAL VOTING
RIGHTS
VANCOUVER, BC - (28
March 2024) In accordance with the FCA's Disclosure Guidance
and Transparency Rules, as at 28 March
2024, the Company's issued share capital consists of
58,127,177
Ordinary
Shares of no par value, each with one voting right. The Company
does not hold any Ordinary Shares in treasury. Therefore, the total
number of voting rights in the Company is 58,127,177.
The above figure of
58,127,177
should be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency
Rules.
For more information,
please contact:
Media
Contact
pr@mydecineinc.com
Investor
Relations
investorrelations@mydecineinc.com
_____________________________
On behalf of the Board of Directors
Joshua
Bartch,
Chief
Executive
Officer
contact@mydecineinc.com
AQSE Corporate
Advisor
Novum Securities
Limited
David Coffman/ George
Duxberry
Tel: +44 (0)207 399
9400
For further
information
about
Mydecine,
please
visit
the
Company's
profile
on
SEDAR
at https://sedar.com/
or
visit the
Company's website at https://www.mydecine.com/.
About Mydecine
Innovations
Group
Inc.
Mydecine
Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address
mental health disorders such as nicotine addiction and
post-traumatic stress disorder (PTSD). The core strategy blends
advanced technology with an elaborate infrastructure for drug
discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions
in areas with considerable unmet needs. By collaborating with some
of the world's leading specialists, the Company aspires to
responsibly speed up the development of
breakthrough
medications
to
provide
patients
with safer
and
more
effective
treatment
solutions.
At
the same
time,
Mydecine's
approach
focuses
on
the
next
generation
of
psychedelic
medicine
by
creating
innovative
compounds with unmatched therapeutic potential through its clinical
trial efforts with world-class scientific and regulatory
expertise.
Learn more at: https://www.mydecine.com/
and
follow
the
Company
on
Twitter,
LinkedIn,
YouTube,
and
Instagram.
